FIG 1.

Longitudinal tracking of NRS384 and LAC hematogenous osteomyelitis. (A and B) In vivo bioluminescence imaging (BLI) of two representative mice (top and bottom rows), performed weekly for 5 weeks, after injection with NRS384 (A) or LAC (B) strains of S. aureus. Arrows highlight BLI foci. (C and D) Quantification of NRS384 (C) and LAC (D) BLI signals measured in each hindlimb (2 data points per mouse) for two separate trials over the 5 weeks postinjection (n = 10 mice per trial) (the BLI threshold is set at 70,000 photons/second). LAC trial 2 purposely terminated at 2 weeks postinjection.